VectivBio Holding AG (VECT) Research

VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.

Market snapshot

Symbol
VECT
Price
$16.87
Day change
+0.12%
Market cap
$1.1B
P/E ratio
-7.94x
52-week range
4.25-16.98
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$18.00

Peer companies

  • Albireo Pharma, Inc. (ALBO)
  • Crescent Biopharma, Inc. (CBIO)
  • Chimerix, Inc. (CMRX)
  • CTI BioPharma Corp. (CTIC)
  • EQRx, Inc. (EQRX)
  • Ethzilla Corp. (ETHZ)
  • Gracell Biotechnologies Inc. (GRCL)
  • Poseida Therapeutics, Inc. (PSTX)

Open VectivBio Holding AG (VECT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.